Company
Immutep Ltd
ASX:IMM
Immutep Ltd (ASX:IMM, NASDAQ:IMMP) is focused on the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. The company's current lead product candidate is eftilagimod alpha, a soluble LAG-3 fusion protein (LAG-3Ig).
5 stories
Immutep valuation increased 16% to $510 million by Edison Investment Research
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
Immutep Ltd raises $6.8 million to fund immuno-oncology clinical development program
The placement price of 2.1 cents represents a 9% discount to its recent trading range.
Immutep receives milestone payment for cancer treatment from Chinese partner
EOC Pharma is undertaking clinical development of eftilagimod alpha in China.